Indivior Stock - technical picture and long-term business model

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 17:16 CET. Details in the imprint.

Indivior (GB00BYZ0C031) focuses on addiction treatment medicines and trades on Nasdaq via its INDV listing. With no fresh corporate headlines today, this report centers on the stock’s technical picture and Indivior’s long-term business model.

What recent data show

Indivior shares most recently closed at $38.28 on Nasdaq on 06/18/2026 in regular trading, according to MarketBeat’s quote data. After hours on the same day, the platform shows an indicative extended-hours level of $37.18.

Based on this quote, MarketBeat reports a market capitalization of roughly $4.8 billion and places Indivior in the pharmaceutical products industry within the broader medical sector. The stock trades under the ticker INDV and is followed by several Wall Street analysts.

Technical picture and range

Technical data from TradingKey indicate that Indivior stock most recently traded at $38.30 at the close on 06/18/2026, up 0.98% on the day. The site also reports a trailing price/earnings ratio of 22.80 and a market capitalization around $4.79 billion.

According to the same TradingKey overview, the shares are currently trading between a support level at $34.12 and a resistance level at $40.76, suggesting a defined trading range. The platform’s momentum score for Indivior stands at 9.44, ranking the stock 18th out of 157 companies in its pharmaceuticals peer set.

On the indicator side, TradingKey notes that Indivior’s moving averages from the 5-day to the 200-day series together show six buy signals and no sell signals. Overall, the site summarizes the daily technical signal as “Buy,” while also highlighting that some individual technical indicators remain mixed.

Long-term positioning and analyst view

Over the past year, eight Wall Street equity research analysts have published ratings on Indivior, according to MarketBeat’s consensus overview. Of these, MarketBeat counts one hold rating, six buy ratings and one strong buy rating.

The platform therefore characterizes the consensus recommendation on INDV shares as “buy,” based on this distribution of opinions. Against this backdrop, the analyst community generally expects growth from Indivior’s addiction-treatment franchise, while also tracking litigation and regulatory risks that are typical for the specialty pharma space.

Institutional-sentiment data from TradingKey point to a high level of professional ownership in the stock, with the latest institutional shareholding proportion reported at above 100% of shares outstanding due to short interest and stock-lending mechanics. The largest disclosed institutional holder on that overview is associated with the Oakmark Select Fund managed by Bill Nygren, with a six-figure share position.

The business behind the stock

Indivior generates most of its revenue from prescription medicines designed to treat opioid use disorder and related addictions, including its flagship buprenorphine-based therapies such as Suboxone and newer formulations. The company also invests in pipeline assets targeting alcohol and stimulant-use disorders, aiming to broaden its addressable market over time.

Where the stock trades today

The shares of Indivior (GB00BYZ0C031) last closed on Nasdaq at $38.28 as of 06/18/2026, 15:59 Eastern Time, according to MarketBeat data.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.